2. Revenue

The following table presents the Company’s revenues by Group and end customer geographical location (dollars in millions):


	Three Months Ended		Three Months Ended
	March 31,		March 31,
	2019		2018
Revenue by Group:
Bruker BioSpin	$	127.8	$	131.8
Bruker CALID		148.2		131.3
Bruker Nano		140.8		123.9
BEST		47.8		45.6
Eliminations		(3.2)		(0.9)
Total revenue	$	461.4	$	431.7


	Three Months Ended		Three Months Ended
	March 31,		March 31,
	2019		2018
Revenue by End Customer Geography:
United States	$	117.6	$	104.8
Germany		42.8		41.5
Rest of Europe		112.3		119.9
Asia Pacific		152.2		126.9
Other		36.5		38.6
Total revenue	$	461.4	$	431.7

Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions):


	Three Months Ended		Three Months Ended
	March 31,		March 31,
	2019		2018
Revenue recognized at a point in time	$	410.5	$	395.2
Revenue recognized over time		50.9		36.5
Total revenue	$	461.4	$	431.7

Remaining Performance Obligations

Remaining performance obligations represent the aggregate transaction price allocated to a promise to transfer a good or service that is fully or partially unsatisfied at the end of the period. As of March 31, 2019, remaining performance obligations were approximately $1,048.9 million. The Company expects to recognize revenue on approximately 79.0% of the remaining performance obligations over the next twelve months and the remaining performance obligations primarily within one to three years.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Company’s unaudited condensed consolidated balance sheets.

Contract assets—Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Billing often occurs subsequent to revenue recognition, resulting in contract assets. Contract assets are generally classified as other current assets in the unaudited condensed consolidated balance sheets. The balance of contract assets as of March 31, 2019 and December 31, 2018 was $31.5 million and $25.9 million, respectively. The increase in the contract asset balance during the three month period ended March 31, 2019 is primarily a result of foreign currency translation and contracts that have been recognized as revenue during the three month period ending March 31, 2019 for which billing cannot contractually occur as of March 31, 2019.

Contract liabilities—The Company often receives cash payments from customers in advance of the Company’s performance, resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the unaudited condensed consolidated balance sheet based on the timing of when revenue recognition is expected. As of March 31, 2019 and December 31, 2018, the contract liabilities were $308.6 million and $288.5 million, respectively. The increase in the contract liability balance during the three month period ended March 31, 2019 is primarily a result of new performance obligations entered into during the three month period. Approximately $75.2 million of the contract liability balance on December 31, 2018 was recognized as revenue during the three month period ended March 31, 2019.